Ocular Hyperemia disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: OCL004 MIFTS: 34	Ocular Hyperemia Categories: Eye diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs Download Expand all tables

Sources

Aliases & Classifications for Ocular Hyperemia

MalaCards integrated aliases for Ocular Hyperemia:

Name: Ocular Hyperemia ¹² ¹⁵ ⁷³

Hyperemia of Conjunctiva ¹²

Hyperemia Eye ¹²

Classifications:

MalaCards categories:
Anatomical: Eye diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹² DOID:1248

SNOMED-CT ⁶⁸ 359610006 76849009

UMLS ⁷³ C0155169

Sources

Summaries for Ocular Hyperemia

MalaCards based summary : Ocular Hyperemia, also known as hyperemia of conjunctiva, is related to adenoid hypertrophy and acid-labile subunit deficiency, and has symptoms including redness of eye An important gene associated with Ocular Hyperemia is TRPV1 (Transient Receptor Potential Cation Channel Subfamily V Member 1), and among its related pathways/superpathways are Pathways in cancer and Development IGF-1 receptor signaling. The drugs Bimatoprost and Timolol have been mentioned in the context of this disorder. Affiliated tissues include eye, and related phenotypes are homeostasis/metabolism and behavior/neurological

Sources

Related Diseases for Ocular Hyperemia

Diseases related to Ocular Hyperemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 12)

#	Related Disease	Score	Top Affiliating Genes
1	adenoid hypertrophy	10.6	SOD1 TRPV1
2	acid-labile subunit deficiency	10.2	IGF2 IGFBP3
3	red-green color blindness	10.2	IGF2 RPE65
4	complete androgen insensitivity syndrome	10.2	IGF2 IGFBP3
5	hereditary wilms' tumor	10.1	ALK IGF2
6	retinal vasculitis	10.1	IFNB1 SOD1
7	fetal macrosomia	10.1	IGF2 IGFBP3
8	central nervous system disease	9.9	IFNB1 SOD1 TRPV1
9	nervous system disease	9.8	IFNB1 SOD1 TRPV1
10	laron syndrome	9.6	IGF2 IGFBP3
11	prader-willi syndrome	9.6	EHMT2 IGF2 IGFBP3
12	ewing sarcoma	8.8	ALK IFNB1 IGF2 IGFBP3

Graphical network of the top 20 diseases related to Ocular Hyperemia:

Sources

Symptoms & Phenotypes for Ocular Hyperemia

UMLS symptoms related to Ocular Hyperemia:

redness of eye

MGI Mouse Phenotypes related to Ocular Hyperemia:

⁴⁶

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.14	PTGER3 ALK IFNB1 IGF2 BCL2L11 IGFBP3
2	behavior/neurological	MP:0005386	10.13	PTGER3 EHMT2 ALK IGF2 IGFBP3 RPE65
3	immune system	MP:0005387	10.11	EHMT2 IFNB1 IGF2 BCL2L11 CD40 PRTN3
4	hematopoietic system	MP:0005397	10.09	EFS EHMT2 IFNB1 IGF2 BCL2L11 CD40
5	endocrine/exocrine gland	MP:0005379	10	EHMT2 ALK BCL2L11 IGF2 IGFBP3 CD40
6	integument	MP:0010771	9.92	PTGER3 ALK IGF2 BCL2L11 IGFBP3 SLC6A2
7	nervous system	MP:0003631	9.85	EHMT2 ALK IFNB1 IGF2 BCL2L11 CD40
8	neoplasm	MP:0002006	9.65	IFNB1 ALK BCL2L11 TRPV1 SOD1
9	pigmentation	MP:0001186	9.26	ALK BCL2L11 IGFBP3 RPE65
10	renal/urinary system	MP:0005367	9.17	PTGER3 IGF2 BCL2L11 IGFBP3 CD40 EFS

Sources

Drugs & Therapeutics for Ocular Hyperemia

Drugs for Ocular Hyperemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 51)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Bimatoprost

Approved, Investigational

Phase 4

155206-00-1

5311027

Timolol

Approved

Phase 4

26839-75-8

33624 5478

Travoprost

Approved

Phase 4,Phase 3

157283-68-6

5282226

Latanoprost

Approved, Investigational

Phase 4

130209-82-4

5282380 5311221

Maleic acid

Experimental

Phase 4

110-16-7

444266

Antihypertensive Agents

Phase 4,Phase 3,Phase 2

Ophthalmic Solutions

Phase 4,Phase 2,Phase 3

Pharmaceutical Solutions

Phase 4,Phase 2,Phase 3

Adrenergic Agents

Phase 4,Phase 3,Phase 2

Adrenergic Antagonists

Phase 4,Phase 2

Adrenergic beta-Antagonists

Phase 4

Anti-Arrhythmia Agents

Phase 4

Neurotransmitter Agents

Phase 4,Phase 3,Phase 2

Anti-Infective Agents

Phase 4

Anti-Infective Agents, Local

Phase 4

Benzalkonium Compounds

Phase 4

Histamine

Approved, Investigational

Phase 3

75614-87-8, 51-45-6

774

Ephedrine

Approved

Phase 3

299-42-3

9294

Fexofenadine

Approved, Investigational

Phase 3

83799-24-0

3348

Loratadine

Approved, Investigational

Phase 3

79794-75-5

3957

Pseudoephedrine

Approved

Phase 3

90-82-4

7028

Adalimumab

Approved

Phase 2, Phase 3

331731-18-1

16219006

Analgesics

Phase 3

Analgesics, Non-Narcotic

Phase 3

Anti-Allergic Agents

Phase 3

Anti-Inflammatory Agents

Phase 3,Phase 2

Anti-Inflammatory Agents, Non-Steroidal

Phase 3

Antirheumatic Agents

Phase 3,Phase 2

Histamine Antagonists

Phase 3

Histamine H1 Antagonists

Phase 3

Histamine H1 Antagonists, Non-Sedating

Phase 3

Histamine Phosphate

Phase 3

51-74-1

65513

Olopatadine Hydrochloride

Phase 3

Peripheral Nervous System Agents

Phase 3

Anti-Asthmatic Agents

Phase 3

Antipruritics

Phase 3

Autonomic Agents

Phase 3

Bronchodilator Agents

Phase 3

Central Nervous System Stimulants

Phase 3

Dermatologic Agents

Phase 3

Nasal Decongestants

Phase 3

Respiratory System Agents

Phase 3

Vasoconstrictor Agents

Phase 3

Antibodies

Phase 2, Phase 3

Antibodies, Monoclonal

Phase 2, Phase 3

Immunoglobulins

Phase 2, Phase 3

Dexamethasone

Approved, Investigational, Vet_approved

Phase 2

50-02-2

5743

Phentolamine

Approved

Phase 2

50-60-2

5775

BB 1101

Phase 2

Dexamethasone acetate

Phase 2

1177-87-3

Interventional clinical trials:

(show all 25)

#	Name	Status	NCT ID	Phase	Drugs
1	A Safety and Efficacy Study of Bimatoprost 0.01% in Primary Open-Angle Glaucoma (POAG) or Ocular Hypertension (OH)	Completed	NCT01594970	Phase 4	Bimatoprost 0.01%
2	A Study of LUMIGAN® RC in the Clinical Setting	Completed	NCT01833741	Phase 4	Bimatoprost 0.01%
3	Efficacy of Changing to DUOTRAV® From Prior Therapy	Completed	NCT01327599	Phase 4	Travoprost 0.004%+Timolol 0.5% ophthalmic solution
4	An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®	Completed	NCT01664039	Phase 4	Travoprost 0.004% ophthalmic solution;Bimatoprost 0.01% ophthalmic solution
5	A Comparison of Xalatan (Latanoprost) to Apo-latanoprost and Co-latanoprost in the Treatment of Glaucoma	Recruiting	NCT02792803	Phase 4	Xalatan;Apo-Latanoprost;Co-Latanoprost
6	Efficacy of Changing to DuoTrav® (Travoprost 0.004%/Timolol 0.5% BAK-Free Fixed Combination) From Prior Therapy	Terminated	NCT01514721	Phase 4	Travoprost/Timolol Maleate BAK-Free Fixed Combination
7	Phase II/III Study of the Efficacy and Safety of MacuCLEAR MC-1101 in Treating DryAge-Related Macular Degeneration	Unknown status	NCT02127463	Phase 2, Phase 3	MC-1101;MC-1101 Vehicle
8	AGN-229666 Ophthalmic Solution in Japanese Patients With Allergic Conjunctivitis	Completed	NCT02161146	Phase 3	AGN-229666;Vehicle to AGN-229666;Olopatadine
9	Effectiveness of Two Preparations of Loratadine + Pseudoephedrine in Patients With Perennial Allergic Rhinitis.	Completed	NCT01228630	Phase 3	Cloratadd-D;Allegra-D
10	An Open-Label, Long-Term Study With AL-4943A Ophthalmic Solution, 0.2% in Patients With Allergic Conjunctivitis	Completed	NCT01037179	Phase 3	Olopatadine Hydrochloride Ophthalmic Solution, 0.2%
11	Effect of Adalimumab for the Treatment of Uveitis in Juvenile Idiopathic Arthritis	Completed	NCT01385826	Phase 2, Phase 3	Anti-tumor necrosis factor alpha monoclonal antibody;placebo
12	A Phase 3 Study of Reproxalap in Subjects With Allergic Conjunctivitis	Recruiting	NCT03494504	Phase 3	Reproxalap Ophthalmic Solution (0.25%);Reproxalap Ophthalmic Solution (0.5%);Vehicle Ophthalmic Solution
13	OTX-16-002: A Phase 3 Study Evaluating the Safety and Efficacy of OTX-TP in Subjects With Open-Angle Glaucoma and Ocular Hypertension	Recruiting	NCT02914509	Phase 3	Travoprost
14	Efficacy and Safety Study of MC-1101 1% TID in the Treatment of Nonexudative Age-Related Macular Degeneration	Terminated	NCT01601483	Phase 2, Phase 3	MC-1101;MC-1101 Vehicle
15	A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Chronic Angle-closure Glaucoma	Unknown status	NCT02152774	Phase 2	Rho-Kinase Inhibitor
16	A Compassionate Case Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Glaucoma Patients With Uncontrolled Intraocular Pressure to Avoid Surgical Intervention	Unknown status	NCT02174991	Phase 2	Rho-Kinase Inhibitor (AR-12286)
17	A Study to Assess the Effect of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Uncontrolled Advanced Glaucoma With Prior Failed Trabeculectomy or Tube Shunt	Unknown status	NCT02173223	Phase 2	Rho-Kinase Inhibitor
18	Phase 2/3 Study Evaluating Efficacy and Safety of OTX-DP for Treatment of Chronic Allergic Conjunctivitis	Completed	NCT02062905	Phase 2	OTX-DP treatment
19	A Study of ADX-102 in Subjects With Allergic Conjunctivitis	Completed	NCT03012165	Phase 2	ADX-102 Ophthalmic Drops (0.5%);ADX-102 Ophthalmic Drops (0.1%);Vehicle of ADX-102 Ophthalmic Drops
20	The Safety and Efficacy of Phentolamine Mesylate Ophthalmic Solution in Subjects With Severe Night Vision Complaints	Completed	NCT01703559	Phase 2	Phentolamine mesylate ophthalmic solution
21	Effectiveness of PR013 Topical Ophthalmic Drops Compared to Vehicle for the Treatment of Allergic Conjunctivitis	Recruiting	NCT03368339	Phase 2	PR013 (0.045%);PR013 (0.06%);Placebo
22	Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer	Terminated	NCT01137071	Phase 2
23	A Study of Bimatoprost 0.01% in the Clinical Setting	Completed	NCT01814761		Bimatoprost 0.01%
24	Non Interventional Study With Primary Open Angle Glaucoma and/or Ocular Hypertension Patients Treated With Xalacom® After Failure of Previous Antiglaucoma Therapy.	Completed	NCT00801437		Xalacom
25	EyeBag Effectiveness in Meibomian Gland Dysfunction	Completed	NCT01870180	Not Applicable

Search NIH Clinical Center for Ocular Hyperemia

Sources

Genetic Tests for Ocular Hyperemia

Sources

Anatomical Context for Ocular Hyperemia

MalaCards organs/tissues related to Ocular Hyperemia:

⁴¹

Eye

Sources

Publications for Ocular Hyperemia

Articles related to Ocular Hyperemia:

#	Title	Authors	Year
1	Seeing red: guiding the management of ocular hyperemia. ( 18528197 )	Saligan L.N....Yeh S.	2008
2	External ocular hyperemia: a quantifiable indicator of spacecraft air quality. ( 8725467 )	Ogle J.W....Cohen K.L.	1996
3	Automatic quantitative measurement of ocular hyperemia. ( 8974839 )	Willingham F.F....Goldstein G.M.	1995
4	Role of nitric oxide in PGF2 alpha-induced ocular hyperemia. ( 7532135 )	Astin M....SelAcn G.	1994
5	Degeneration release of norepinephrine causes transient ocular hyperemia mediated by prostaglandins. ( 4692259 )	Neufeld A.H....Sears M.L.	1973

Sources

Genes for Ocular Hyperemia

Genes related to Ocular Hyperemia (0 elite genes):

(show all 14)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	TRPV1	Transient Receptor Potential Cation Channel Subfamily V Member 1	Protein Coding	18.62	DISEASES inferred ¹⁵ ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
2	EHMT2	Euchromatic Histone Lysine Methyltransferase 2	Protein Coding	15.22	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
3	SLC6A2	Solute Carrier Family 6 Member 2	Protein Coding	15.06	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
4	RPE65	RPE65, Retinoid Isomerohydrolase	Protein Coding	14.83	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
5	BCL2L11	BCL2 Like 11	Protein Coding	14.17	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
6	SOD1	Superoxide Dismutase 1	Protein Coding	13.93	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
7	IGFBP3	Insulin Like Growth Factor Binding Protein 3	Protein Coding	13.74	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
8	CD40	CD40 Molecule	Protein Coding	13.7	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
9	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	13.59	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
10	IGF2	Insulin Like Growth Factor 2	Protein Coding	13.55	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
11	PTGER3	Prostaglandin E Receptor 3	Protein Coding	13.54	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
12	IFNB1	Interferon Beta 1	Protein Coding	13.39	DISEASES inferred ¹⁵ GeneCards inferred via : DISEASES inferred (show sections)
13	EFS	Embryonal Fyn-Associated Substrate	Protein Coding	5.02	DISEASES inferred ¹⁵
14	PRTN3	Proteinase 3	Protein Coding	3.79	DISEASES inferred ¹⁵

Sources

Variations for Ocular Hyperemia

Sources

Expression for Ocular Hyperemia

Search GEO for disease gene expression data for Ocular Hyperemia.

Sources

Pathways for Ocular Hyperemia

Pathways related to Ocular Hyperemia according to GeneCards Suite gene sharing:

#	Super pathways	Score	Top Affiliating Genes
1	Pathways in cancer ³⁷	12.18	ALK BCL2L11 IGF2 PTGER3
2	Development IGF-1 receptor signaling ²² Show member pathways Signal transduction AKT signaling ²²	10.9	BCL2L11 IGF2 IGFBP3
3	Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) ⁶⁶	10.28	IGF2 IGFBP3

Sources

GO Terms for Ocular Hyperemia

Cellular components related to Ocular Hyperemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	plasma membrane	GO:0005886	9.32	ALK CD40 EFS IGF2 PRTN3 PTGER3

Biological processes related to Ocular Hyperemia according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of apoptotic process	GO:0043065	9.71	BCL2L11 IGFBP3 SOD1 TRPV1
2	regulation of apoptotic process	GO:0042981	9.67	ALK BCL2L11 CD40 IGFBP3
3	activation of MAPK activity	GO:0000187	9.61	ALK IGF2 SOD1
4	B cell proliferation	GO:0042100	9.48	CD40 IFNB1
5	response to pain	GO:0048265	9.46	SLC6A2 TRPV1
6	cellular response to ATP	GO:0071318	9.32	SOD1 TRPV1
7	myeloid cell homeostasis	GO:0002262	9.26	BCL2L11 SOD1
8	positive regulation of MAPK cascade	GO:0043410	9.26	ALK CD40 IGF2 IGFBP3
9	regulation of organ growth	GO:0046620	9.16	BCL2L11 SOD1
10	response to nutrient levels	GO:0031667	8.92	CD40 EHMT2 IGF2 SOD1

Sources

Sources for Ocular Hyperemia

¹ BioSystems

² BitterDB

³ CDC

⁴ Cell Signaling Technology

⁵ ClinicalTrials

⁶ ClinVar

⁷ CNVD

⁸ Cochrane Library

⁹ Cosmic

¹⁰ dbSNP

¹¹ DGIdb

¹² Disease Ontology

¹³ diseasecard

¹⁴ DiseaseEnhancer

¹⁵ DISEASES

¹⁶ DrugBank

¹⁷ ExPASy

¹⁸ FDA Approved Drugs

¹⁹ FMA

²⁰ GeneAnalytics

²¹ GeneCards

²² GeneGo (Thomson Reuters)

²³ GeneHancer via GeneCards

²⁴ GeneReviews

²⁵ Genetics Home Reference

²⁶ GenomeRNAi

²⁷ GEO DataSets

²⁸ GO

²⁹ GTR

³⁰ HGMD

³¹ HMDB

³² HPO

³³ ICD10

³⁴ ICD10 via Orphanet

³⁵ ICD9CM

³⁶ IUPHAR

³⁷ KEGG

³⁸ LifeMap

³⁹ LncRNADisease

⁴⁰ LOVD

⁴¹ MalaCards

⁴² MedGen

⁴³ MedlinePlus

⁴⁴ MeSH

⁴⁵ MESH via Orphanet

⁴⁶ MGI

⁴⁷ miR2Disease

⁴⁸ NCBI Bookshelf

⁴⁹ NCI

⁵⁰ NCIt

⁵¹ NDF-RT

⁵² NIH Clinical Center

⁵³ NIH Rare Diseases

⁵⁴ NINDS

⁵⁵ Novoseek

⁵⁶ Novus Biologicals

⁵⁷ OMIM

⁵⁸ OMIM via Orphanet

⁵⁹ Orphanet

⁶⁰ PathCards

⁶¹ PharmGKB

⁶² PubMed

⁶³ PubMed Health

⁶⁴ QIAGEN

⁶⁵ R&D Systems

⁶⁶ Reactome

⁶⁷ Sino Biological

⁶⁸ SNOMED-CT

⁶⁹ SNOMED-CT via HPO

⁷⁰ SNOMED-CT via Orphanet

⁷¹ TGDB

⁷² Tocris

⁷³ UMLS

⁷⁴ UMLS via Orphanet

⁷⁵ UniProtKB/Swiss-Prot

⁷⁶ Wikipedia